Phase I study of a chloroquine–gemcitabine combination in patients with metastatic or unresectable pancreatic cancer

Purpose Following a previously published pre-clinical validation, this phase I study evaluated the safety, maximum tolerated dose, anti-tumour activity and immune status of a gemcitabine–chloroquine combination as a first- or late-line treatment in patients with metastatic or unresectable pancreatic cancer.